ClinicalTrials.gg

Program

senicapoc

Also written as “ICA-17043”, “Senicapoc” and “Low Dose ICA-17043”.

Its studies are mostly in Anemia, Sickle Cell · Asthma, Exercise-Induced · Asthma, led by 2 companies.

Furthest: phase 3, since Feb 1, 20056 company-led studies, 1 open or runningNext primary completion: Oct 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Icagen50 open or runningphase 3since Feb 1, 2005Jul 8, 2002none ahead
Biossil11 open or runningphase 2since Nov 13, 2025Nov 13, 2025Oct 2029phase 2 · NCT07282210

Also a collaborator on its studies: Johnson & Johnson.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 8, 2002First study: phase 2 study in Anemia, Sickle CellNew to IcagenIcagen · NCT00040677 · 90 enrolled · United States
  2. Feb 1, 2005Phase 3 study in Anemia, Sickle CellIcagen · NCT00102791 · 297 enrolled · United States, Brazil, France and more
  3. Feb 21, 2006Phase 3 study in Anemia, Sickle CellIcagen · NCT00294541 · 51 enrolled · United States
  4. Mar 12, 20092 phase 2 studiesIcagen · NCT00861211, NCT00861185
  5. Nov 13, 2025Biossil's first study: phase 2 study in Anemia, Sickle CellNew to BiossilBiossil · NCT07282210 · 65 planned · Canada

Ahead

  1. Oct 2029Primary completion: phase 2 study in Anemia, Sickle CellBiossil · NCT07282210

TargetBeta

KCNN4 →read by rule
“An orally bioavailable inhibitor of the calcium-activated potassium channel KCa3.1 (Gardos channel; KCNN4; IK-1; SK4), ”NCIt, by rule
“Intermediate conductance calcium-activated potassium channel protein 4 blocker”ChEMBL 37, by rule

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07282210Anemia, Sickle Cell · Canada2RecruitingBiossilOct 202965
NCT00861211Asthma · United Kingdom2CompletedIcagenMar 200934
NCT00861185Asthma, Exercise-Induced · United States2CompletedIcagenJul 200969
NCT00294541Anemia, Sickle Cell · United States3TerminatedIcagen51
NCT00102791Anemia, Sickle Cell · United States, Brazil, France and more3TerminatedIcagen297
NCT00040677Anemia, Sickle Cell · United States2CompletedIcagenNov 200390

How it is read

Names in the registry

  • “senicapoc”, 2 entries
  • “ICA-17043”, 2 entries
  • “Senicapoc”, 1 entry
  • “Low Dose ICA-17043”, 1 entry
  • “High dose ICA-17043”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.